Evan Cantor, MD

American Board of Pediatrics - Pediatrics

American Board of Pediatrics - Pediatric Hematology-Oncology (Pending)

Assistant Professor of Pediatrics, University of Connecticut School of Medicine

• View Dr. Cantor's bibliography
• Cantor E, Koschmann C. “Multiplatform Molecular Profiling: A Precision Medicine Victory Built on Cytotoxic Chemotherapy” The Cancer Journal. 25(2):80, Mar 2019
• Bruzek A, Ravi K, Muruganand A, Wadden J, Babila C, Cantor E, Tunkle L, Wierzbicki K, Stallard S, Dickson R, Wolfe I, Mody R, Schwartz J, Franson A, Robertson P, Muraszko K, Maher C, Garton H, Qin T, Koschmann C* (2020). Use of novel, hand-held, electronic DNA analysis platform to quantify multi-gene molecular response in CSF of patients with high-grade glioma. Clinical Cancer Research. 2020. DOI: 10.1158/1078-0432.CCR-20-2066
• Pratt, D., Kumar-Sinha, C., Cieślik, M., Mehra, R., Xiao, H., Shao, L., Franson, A., Cantor, E., Chinnaiyan, A.M., Mody, R. and Abdullaev, Z., 2021. “A novel ATXN1-DUX4 fusion expands the spectrum of ‘CIC-rearranged sarcoma’of the CNS to include non-CIC alterations.” Acta Neuropathologica, 141(4), pp.619-622.
• Cantor E, Wierzbicki K, Tarapore RS, Ravi K, Thomas C, Cartaxo R, Yadav VN, Ravindran R, Bruzek AK, Wadden J, John V, Babila CM, Cummings JR, Kawakibi AR, Ji S, Ramos J, Paul A, Walling D, Leonard M, Robertson P, Franson A, Mody R, Garton HJL, Venetti S, Odia Y, Kline C, Vitanza NA, Khatua S, Mueller S, Allen JE, Gardner S, Koschmann C. Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma. Neuro Oncol. 2022 Feb 6:noac030. doi: 10.1093/neuonc/noac030. Epub ahead of print. PMID: 35137228.
• Cantor E, Meyer A, Morris SM, Weisenberg JLZ, Brossier NM. Dose-dependent seizure control with MEK inhibitor therapy for progressive glioma in a child with neurofibromatosis type 1. Childs Nerv Syst. 2022 Jun 1. doi: 10.1007/s00381-022-05571-y. Epub ahead of print. PMID: 35648241.